



September 7, 2016

## **Amarin to Present at the Rodman & Renshaw 18th Annual Global Investment Conference**

BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the Rodman & Renshaw 18th Annual Global Investment Conference in New York City on Tuesday, September 13, 2016, at 3:50 p.m. ET.

A live audio webcast of the presentation will be available at:

<http://wsw.com/webcast/rrshq26/amrn>

### **About Amarin**

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes a commitment to an ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin's first FDA-approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa, visit [www.vascepa.com](http://www.vascepa.com). For more information about Amarin, visit [www.amarincorp.com](http://www.amarincorp.com).

### **Availability of Other Information about Amarin**

Investors and others should note that we communicate with our investors and the public using our company website ([www.amarincorp.com](http://www.amarincorp.com)), our investor relations website (<http://www.amarincorp.com/investor-splash.html>), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin contact information

Investor Relations:

Kathryn McNeil

Investor Relations and Corporate Communications

Amarin Corporation plc

In U.S.: +1 (908) 719-1315

[investor.relations@amarincorp.com](mailto:investor.relations@amarincorp.com)

Lee M. Stern

Trout Group

In U.S.: +1 (646) 378-2922

[lstern@troutgroup.com](mailto:lstern@troutgroup.com)

Media Inquiries:

Ovidio Torres

Finn Partners

In U.S.: +1 (312) 329 3911

[Ovidio.torres@finnpartners.com](mailto:Ovidio.torres@finnpartners.com)

 Primary Logo

Source: Amarin Corporation plc

News Provided by Acquire Media